Tumour heterogeneity refers to the fact that different tumour cells can show distinct
morphological and phenotypic profiles, including cellular morphology, gene expression …

In patients with cancer, individualized treatment strategies are generally guided by an
analysis of molecular biomarkers. However, genetic instability allows tumor cells to lose …

Developments in genomic techniques have provided insight into the remarkable genetic
complexity of malignant tumours. There is increasing evidence that solid tumours may …

Tumor heterogeneity is a major hindrance in cancer classification, diagnosis and treatment.
Recent technological advances have begun to reveal the true extent of its heterogeneity …

Tumor heterogeneity is a confusing finding in the assessment of neoplasms, potentially
resulting in inaccurate diagnostic, prognostic and predictive tests. This tumor heterogeneity …

Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction.
Accurately detecting heterogeneity for the development of biomarkers and the detection of …

Intratumor heterogeneity represents a major obstacle to effective cancer treatment and
personalized medicine. However, investigators are now elucidating intratumor heterogeneity …

Simple Summary Cancer heterogeneity, which occurs in most cancer patients, has been
known and studied by experienced pathologists since the early 19th century. Intratumoral …

Cancer heterogeneity, long recognized as an important clinical determinant of patient
outcomes, was poorly understood at a molecular level. Genomic studies have significantly …

Intratumor heterogeneity (ITH) is a biomarker of tumor progression, metastasis, and immune
evasion. Previous studies evaluated ITH mostly based on DNA alterations. Here, we …